BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Feb 07, 2011
 |  BC Week In Review  |  Company News  |  Sales & Marketing

Valeant Pharmaceuticals, GlaxoSmithKline sales and marketing update

Valeant's Biovail Laboratories International SRL subsidiary will pay $300 million in cash to partner GlaxoSmithKline to acquire all U.S. and Canadian rights to non-ophthalmic topical formulations of cold sore...

Read the full 123 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >